- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01981174
A Pilot Study of Needle Size and Pain Perception With Botulinum Toxin A Injections
December 2, 2021 updated by: Murad Alam, Northwestern University
The Effect of Needle Size on Pain Perception in Patients Treated With Botulinum Toxin A Injections
The purpose of this study is to compare the levels of pain resulting from injections of Botox® for wrinkles on the forehead and between the eyes using two different sized needles (32 gauge and 30 gauge needles).
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
Subjects will be screened, assessed, and randomized to be injected with onabotulinum toxin A using a 30-gauge needle on one side of the face and injected using a 32-gauge needle on the other side during their first clinic visit.
This study is a pilot study designed to determine feasibility of these procedures.
Study Type
Interventional
Enrollment (Actual)
20
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Illinois
-
Chicago, Illinois, United States, 60611
- Northwestern University Department of Dermatology
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
25 years to 70 years (Adult, Older Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
Female
Description
Inclusion Criteria:
- In good health
- Is a female
- Is 25-70 years of age
- Has moderate dynamic forehead/glabellar wrinkles
- Has willingness and the ability to understand and provide informed consent and communicate with the study staff
Exclusion Criteria:
- Younger than 25 or older than 70 years of age
- Pregnant or lactating
- Is a male
Has received the following treatments in the forehead or glabellar region:
- botulinum toxin injections in the past 6 months
- ablative laser procedure in the past 6 months
- radiofrequency device treatment in the past 6 months
- ultrasound device treatment in the past 6 months
- medium to deep chemical peel in the past 6 months
- temporary soft tissue augmentation material in the area to be treated in the past year
- semi-permanent soft tissue augmentation material in the area to be treated in the past 2 years
- permanent soft tissue augmentation material in the area to be treated
- Has an active infection in the forehead or glabellar region (excluding mild acne)
- Is allergic to cow's-milk protein
- Is allergic to albumin
- Taking aminoglycoside
- Is currently using anticoagulation therapy
- Has a history of bleeding disorders
- Has a mental illness
- Unable to understand the protocol or to give informed consent
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Single Group Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: 30-gauge needle
Subjects will be screened, assessed, and randomized to be injected with onabotulinum toxin A using a 30-gauge needle on one side of the face and injected using a 32-gauge needle on the other side during their first clinic visit.
All needles would be luer lock, ½ inch length, and attached to separate 1cc syringes.
Injection depth would be 1-2mm, dermal, and the angle of incidence would be perpendicular.
|
|
Active Comparator: 32-gauge needle
Subjects will be screened, assessed, and randomized to be injected with onabotulinum toxin A using a 30-gauge needle on one side of the face and injected using a 32-gauge needle on the other side during their first clinic visit.
All needles would be luer lock, ½ inch length, and attached to separate 1cc syringes.
Injection depth would be 1-2mm, dermal, and the angle of incidence would be perpendicular.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Visual analog score (VAS) pain rating after each side is injected
Time Frame: 1 hour on Treatment day
|
Subjects will rate pain using the visual analog score (VAS 1-10) after each side is injected using the 30 or 32 gauge needles.
Lower values represents less pain; higher values represents more pain.
|
1 hour on Treatment day
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
November 1, 2013
Primary Completion (Actual)
January 1, 2014
Study Completion (Actual)
January 1, 2014
Study Registration Dates
First Submitted
November 5, 2013
First Submitted That Met QC Criteria
November 5, 2013
First Posted (Estimate)
November 11, 2013
Study Record Updates
Last Update Posted (Actual)
December 6, 2021
Last Update Submitted That Met QC Criteria
December 2, 2021
Last Verified
December 1, 2021
More Information
Terms related to this study
Other Study ID Numbers
- STU84470
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pain
-
Flowonix MedicalApproved for marketingBack Pain | Leg Pain | Trunk Pain | Intractable Pain | Arm Pain
-
University Hospital Schleswig-HolsteinZealand University Hospital; European Regional Development Fund; Design School...CompletedPain, Acute | Pain, Chronic | Pain Measurement | Pain, CancerGermany
-
Dr. Negrin University HospitalCompletedPostoperative Pain, Acute | Postoperative Pain, ChronicSpain
-
George Washington UniversityRecruitingCervical Fusion | Pain, Back | Pain, Neck | Myofacial PainUnited States
-
Dow University of Health SciencesRecruitingLow Back Pain | Chronic Low-back Pain | Low Back Pain, Mechanical | Mechanical Low Back Pain | Pain, Chronic | Pain, Back | Lower Back Pain Chronic | CLBP - Chronic Low Back PainPakistan
-
Universitat Jaume ICompletedPain, Acute | Pain, Chronic | OncologySpain
-
Atatürk Chest Diseases and Chest Surgery Training...RecruitingPostoperative Pain | Postoperative Pain, Acute | Postoperative Pain, Chronic | VATSTurkey
-
Janssen Research & Development, LLCCompletedPain, Radiating | Pain, Burning | Pain, Crushing | Pain, Migratory | Pain, SplittingUnited States, France, Spain, Poland, Portugal
-
susanne beckerSNSFCompletedLow Back Pain | Pain, Acute | Pain, ChronicSwitzerland
-
University of Campinas, BrazilCompletedPREGNANCY | LUMBAR BACK PAIN | PELVIC PAIN
Clinical Trials on 30-gauge needle
-
Postgraduate Institute of Medical Education and...All India Institute of Medical Sciences, New Delhi; Rajiv Gandhi Cancer Institute... and other collaboratorsCompleted
-
Yale UniversityRothman Institute OrthopaedicsCompletedPain | Needle InjuryUnited States
-
National University of MalaysiaUnknown
-
Prof. Dr. Peter StalmansCompleted
-
Medical University of South CarolinaJohns Hopkins University; University of North Carolina; Cook Endoscopy; Thoraxklinik-Heidelberg...CompletedQuantity of Tissue Obtained | Quality of Tissue Obtained | Ease of Use of 22-gauge ProCore EBUS Needles and the Standard 22-gauge NeedlesUnited States
-
The Ludwig Boltzmann Institute of Retinology and...Completed
-
Retina Health CenterGenentech, Inc.; California Retina ConsultantsUnknown
-
Samsung Medical CenterCompletedPancreatic NeoplasmsKorea, Republic of
-
Samsung Medical CenterOlympusCompletedPancreatic CancerKorea, Republic of
-
Geisinger ClinicCompleted